The Journal of Practical Medicine >
The effect of vanadyl bis（acetylacetonato） on the proliferation and invasion of human adrenocortical carcinoma cells
Received date: 2024-12-24
Online published: 2025-03-31
Objective To investigate the effects of bis（acetylacetonato）oxovanadium（IV） ［VO（acac）?］ on human adrenocortical carcinoma cell lines SW?13 and NCI?H295R in vitro， aiming to determine whether VO（acac）? promotes or inhibits the proliferation， migration， and invasion of these cells. Methods SW?13 and NCI?H295R cells in logarithmic growth phase were exposed to VO（acac）? at concentrations of 6.25， 12.5， 25， 50， 75， 100， and 200 μmol/L for 24 and 48 hours， respectively. Mitotane served as the positive control. Cell viability was assessed using the CCK?8 assay to evaluate the effects of VO（acac）? on SW?13 and NCI?H295R cells. Subsequently， cells were treated with VO（acac）? at concentrations of 0， 6.25， 12.5， and 25 μmol/L for 48 hours， and flow cytometry was employed to investigate the impact of VO（acac）? on apoptosis. The migratory ability of the cells was evaluated using a wound healing assay， while their invasive capacity was assessed via a Transwell assay. Additionally， the clonogenic assay was used to determine the proliferative potential of SW?13 and NCI?H295R cells following VO（acac）? treatment. Results The CCK?8 results demonstrated that VO（acac）2 inhibited the viability of SW?13 and NCI?H295R cells in a time? and concentration?dependent manner. Specifically， the half?maximal inhibitory concentrations （IC50） for VO（acac）2 against SW?13 cells were 62.98 ± 6.67 μmol/L after 24 hours and （14.61 ± 1.66） μmol/L after 48 hours of treatment， while the corresponding IC50 values for NCI?H295R cells were 46.78 ± 7.89 μmol/L and 12.61 ± 2.98 μmol/L， respectively. Flow cytometry analysis revealed that VO（acac）2 induced apoptosis in both SW?13 and NCI?H295R cells in a concentration?dependent manner （P < 0.05）. The wound healing assay indicated a significant reduction in the migratory rate of SW?13 and NCI?H295R cells with increasing concentrations of VO（acac）2 （P < 0.05）. Transwell assay results showed that VO（acac）2 significantly inhibited the invasive ability of SW?13 and NCI?H295R cells in a concentration?dependent fashion. Finally， the clonogenic assay confirmed that VO（acac）2 suppressed the proliferative capacity of SW?13 and NCI?H295R cells in a concentration?dependent manner. Conclusion VO（acac）2 inhibits the proliferation， migration， and invasion of human adrenocortical carcinoma cells （SW?13 and NCI?H295R）， while inducing apoptosis in these cell lines.
Meiyu GAN , Chunjiao WU , Jingyi QIN , Zuojie. LUO . The effect of vanadyl bis（acetylacetonato） on the proliferation and invasion of human adrenocortical carcinoma cells[J]. The Journal of Practical Medicine, 2025 , 41(6) : 781 -789 . DOI: 10.3969/j.issn.1006-5725.2025.06.002
| 1 | BERRUTI A， BAUDIN E， GELDERBLOM H， et al. ESMO Guidelines Working Group. Adrenal cancer： ESMO Clinical Practice Guidelines for diagnosis， treatment and follow-up［J］. Ann Oncol， 2012，23 （）：vii 131-138. doi:10.1093/annonc/mds231 |
| 2 | BERRUTI A， GRISANTI S， PULZER A， et al. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma［J］. J Clin Endocrinol Metab， 2017，102（4）：1358-1365. doi:10.1210/jc.2016-2894 |
| 3 | TERZOLO M， ANGELI A， FASSNACHT M， et al. Adjuvant mitotane treatment for adrenocortical carcinoma［J］. N Engl J Med， 2007，356（23）：2372-2380. doi:10.1056/nejmoa063360 |
| 4 | LU D， YU N， MA X， et al. An ectopic adrenocortical adenoma in renal hilum presenting with Cushing's syndrome： A case report and literature review［J］. Medicine （Baltimore）， 2018，97（50）：e13322. doi:10.1097/md.0000000000013322 |
| 5 | BUSSEY K J， BAPAT A， LINNEHAN C， et al. Targeting polo-like kinase 1， a regulator of p53， in the treatment of adrenocortical carcinoma［J］. Clin Transl Med， 2016，5（1）：1. doi:10.1186/s40169-015-0080-3 |
| 6 | ZHENG S， CHERNIACK A D， DEWAL N， et al. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma［J］. Cancer Cell， 2016，30（2）：363. |
| 7 | DATTA J， ROSES R E. Surgical Management of Adrenocortical Carcinoma： An Evidence-Based Approach［J］. Surg Oncol Clin N Am， 2016，25（1）：153-170. doi:10.1016/j.soc.2015.08.011 |
| 8 | GONZALEZ R J， TAMM E P， NG C， et al. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma［J］. Surgery， 2007，142（6）：867-875，discussion 867-875. doi:10.1016/j.surg.2007.09.006 |
| 9 | HUGHES M S， LO W M， BERESNEV T， et al. A Phase II Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Adrenocortical Carcinoma［J］. J Surg Res， 2018，232：383-388. doi:10.1016/j.jss.2018.06.012 |
| 10 | MEGERLE F， HERRMANN W， SCHLOETELBURG W， et al. German ACC Study Group. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma［J］. J Clin Endocrinol Metab， 2018，103（4）：1686-1695. doi:10.1210/jc.2017-02591 |
| 11 | 唐玲，张英，申竹芳，等. 钒类化合物的抗糖尿病作用［J］. 中国临床药理学杂志， 2001，17（4）：298-302. doi:10.3969/j.issn.1001-6821.2001.04.015 |
| 12 | BRACKEN W M， SHARMA R P， ELSNER Y Y. Vanadium accumμLation and subcellμLar distribution in relation to vanadate induced cytotoxicity in vitro［J］. Cell Biol Toxicol， 1985，1（4）：259-268. doi:10.1007/bf00118191 |
| 13 | MEGERLE F， HERRMANN W， SCHLOETELBURG W， et al. German ACC Study Group. Mitotane Monothera in Patients With Advanced Adrenocortical Carcinoma［J］. J Clin Endocrinol Metab， 2018，103（4）：1686-1695. doi:10.1210/jc.2017-02591 |
| 14 | REHDER D. The potentiality of vanadium in medicinal applications［J］. Future Med Chem， 2012，4（14）：1823-1837. doi:10.4155/fmc.12.103 |
| 15 | KIELER J， GROMEK A， NISSEN N I. Studies on the antineoplastic effect of vanadium salts［J］. Acta Chir Scand Suppl， 1965，343：154-164. |
| 16 | TSIANI E， FANTUS I G. Vanadium compounds biological actions and potential as pharmacological agents［J］.Trends Endocrinol Metab， 1997，8（2）：51-58. doi:10.1016/s1043-2760(96)00262-7 |
| 17 | PISANO M， ARRU C， SERRA M， et al. Antiproliferative activity of vanadium compounds： effects on the major malignant melanoma molecμLar pathways［J］. Metallomics， 2019，11（10）：1687-1699. doi:10.1039/c9mt00174c |
| 18 | DANKHOFF K， AHMAD A， WEBER B， et al. Anticancer properties of a new non-oxido vanadium（IV） complex with a catechol-modified 3，3'-diindolylmethane ligand［J］. J Inorg Biochem， 2019，194：1-6. doi:10.1016/j.jinorgbio.2019.02.005 |
| 19 | ZHANG Y， WANG L， ZENG K， et al.Vanadyl complexes discriminate between neuroblastoma cells and primary neurons by inducing cell-specific apoptotic pathways［J］. J Inorg Biochem， 2018，188：76-87. doi:10.1016/j.jinorgbio.2018.08.005 |
| 20 | WU J X， HONG Y H， YANG X G. Bis（acetylacetonato）-oxidovanadium（IV） and sodium metavanadate inhibit cell proliferration via ROS-induced sustained MAPK/ERK activation but with elevated AKT activity in human pancreatic cancer AsPC-1 cells［J］. J Aiol Inorg Chem， 2016，21（8）：919-929. doi:10.1007/s00775-016-1389-0 |
| 21 | GOLDWASER I， GEFEL D， GERSHONOV E， et al. Insulin-like effects of vanadium： Basic and clinical implications［J］. J Inorg Biochem， 2000，80（1-2）：21-25. doi:10.1016/s0162-0134(00)00035-0 |
| 22 | MAKINEN M W， BRADY M J. Structural origins of the insulin-mimetic activity of bis（acetylacetonato）oxovanadium（IV）［J］. J Biol Chem， 2002，277（14）：12215-12220. doi:10.1074/jbc.m110798200 |
| 23 | REUL B A， AMIN S S， BUCHET J P，et al. Effects of vanadium complexes with organic ligands on glucose metabolism： A comparison study in diabetic rats［J］. Br J Pharmacol， 1999，126（2）：467-77. doi:10.1038/sj.bjp.0702311 |
| 24 | 田生平，王崇山，杨伟忠. 肾上腺皮质肿瘤中mTOR信号通路的表达及其与细胞侵袭、血管新生的关系［J］. 海南医学院学报， 2018，24（11）：1120-1123. doi:10.13210/j.cnki.jhmu.20180425.002 |
| 25 | ?ISMAN P， ?AHIIN A B， PEYNIRCI H， et al. Adrenocortical carcinoma： Single center experience［J］. Turk J Urol， 2017，43（4）：462-469. doi:10.5152/tud.2017.81598 |
| 26 | WANG S， GAO W C， CHEN S S， et al. Primary site surgery for metastatic adrenocortical carcinoma improves survival outcomes： an analysis of a popμLation-based database［J］. Onco Targets Ther， 2017， 10：5311-5315. doi:10.2147/ott.s147352 |
| 27 | MUKHERJEE B， PATRA B， MAHAPATRA S， et al. Vanadium-an element of atypical biological significance［J］. Toxicol Lett，2004，150（2）：135-143. doi:10.1016/j.toxlet.2004.01.009 |
| 28 | REHDER D. The role of vanadium in biology［J］. Metallomics，2015，7（5）：730-742. doi:10.1039/c4mt00304g |
| 29 | BISHAYEE A， WAGHRAY A， PATEL M A， et al. Vanadium in the detection， prevention and treatment of cancer： The in vivo evidence［J］. Cancer Lett， 2010，294（1）：1-12. doi:10.1016/j.canlet.2010.01.030 |
| 30 | PETANIDIS S， KIOSEOGLOU E， SALIFOGLOU A. Metallodrugs in Targeted Cancer Therapeutics： Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks［J］. Curr Med Chem， 2019，26（4）：607-623. doi:10.2174/0929867324666171116125908 |
| 31 | SANCHEZ-LOMBARDO I， ALVAREZ S， MCLAUCHLAN C C，et al.Evaluating transition state structures of vanadium-phosphatase protein complexes using shape analysis［J］. J Inorg Biochem， 2015，147：153-164. doi:10.1016/j.jinorgbio.2015.04.005 |
| 32 | HUANG C， ZHANG Z， DING M，et al.Vanadate induces p53 transactivation through hydrogen peroxide and causes apoptosis［J］. J Biol Chem， 2000，275（42）：32516-32522. doi:10.1074/jbc.m005366200 |
| 33 | HUANG C， DING M， LI J， et al. Vanadium-induced nuclear factor of activated T cells activation through hydrogen peroxide［J］.J Biol Chem， 2001，276（25）：22397-22403. doi:10.1074/jbc.m010828200 |
| 34 | MARKOPOULOU， KONTARGIRIS E， BATSI C， et al.Vanadium-induced apoptosis of HaCaT cells is mediated by c-fos and involves nuclear accumμLation of clusterin［J］. FEBS J， 2009，276（14）：3784-3799. doi:10.1111/j.1742-4658.2009.07093.x |
| 35 | ZHANG Z， CHEN F， HUANG C， et al.Vanadate induces G2/M phase arrest in p53-deficient mouse embryo fibroblasts［J］. J Environ Pathol Toxicol Oncol， 2002，21（3）：223-231. doi:10.1615/jenvironpatholtoxicoloncol.v21.i3.30 |
| 36 | WANG Q， LIU T T， FU Y，et al.Vanadium compounds discriminate hepatoma and normal hepatic cells by differential regulation of reactive oxygen species［J］. J Biol Inorg Chem， 2010，15（7）：1087-1097. doi:10.1007/s00775-010-0668-4 |
| 37 | ABAKUMOVA O I U， PODOBED O V， BELIAEVA N F， et al. Anticancer activity of oxovanadium compounds［J］. Biomed Khim， 2013，59（3）：305-320. doi:10.18097/pbmc20135903305 |
| 38 | FU Y， WANG Q， YANG X G， et al. Vanadyl bisacetylacetonate induced G1/S cell cycle arrest via high-intensity ERK phosphorylation in HepG2 cells［J］. J Biol Inorg Chem， 2008，13（6）：1001-1009. doi:10.1007/s00775-008-0387-2 |
| 39 | WU J X， HONG Y H， YANG X G. Bis（acetylacetonato）-oxidovanadium（IV） and sodium metavanadate inhibit cell proliferation via ROS-induced sustained MAPK/ERK activation but with elevated AKT activity in human pancreatic cancer AsPC-1 cells［J］. J Biol Inorg Chem， 2016， 21（8）：919-929. doi:10.1007/s00775-016-1389-0 |
| 40 | SHUKLA R， BARVE V， PADHYE S， et al. Reduction of oxidative stress induced vanadium toxicity by complexing with a flavonoid， quercetin： A pragmatic therapeutic approach for diabetes［J］. Biometals， 2006，19（6）：685-693. doi:10.1007/s10534-006-9005-3 |
/
| 〈 |
|
〉 |